63 hasil untuk "Weide, Benjamin"
Menampilkan 1–20 · 0,32 detik · RSS
-
Artikel Jurnal Teks lengkap
Intralesional treatment of metastatic melanoma: a review of therapeutic options
Intralesional therapy of melanoma patients with locally advanced metastatic disease is attracting increasing interest, not least due to its ability to lead to both direct tumor cell killing and the stimulation of both a local and a systemic immune response. An obvious pre-requisite for this type of…
-
Artikel Jurnal Teks lengkap
Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters
Heat shock proteins (hsps) have been studied in numerous cancer types, but a clear view of their clinical relevance in melanoma remains elusive. Therefore, the aim of this study was to investigate the expression of hsps in melanoma with respect to patient clinical parameters. Using Western…
-
Artikel Jurnal Teks lengkap
Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
Despite remarkable recent progress in treating solid cancers, especially the success of immunomodulatory antibody therapies for numerous different cancer types, it remains the case that many patients fail to respond to treatment. It is therefore of immense importance to identify biomarkers…
-
Artikel Jurnal Teks lengkap
Monocytic myeloid-derived suppressor cells in advanced melanoma patients
The percentage of circulating CD14(+)CD11b(+)HLA-DR(−/low) myeloid-derived suppressor cells (MDSCs) inversely correlates with survival among advanced melanoma patients. High levels of MDSCs are associated with the absence of T lymphocytes specific for melanoma-derived antigens, implying a causal…
-
Artikel Jurnal Teks lengkap
Limited efficacy of intratumoral IL-2 applied to large melanoma metastases
-
Artikel Jurnal Teks lengkap
High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera
The characterization of peptides bound to HLA (human leukocyte antigen) class I is of fundamental importance for understanding CD8+ T cell-driven immunological processes and for the development of immunomodulatory therapeutic strategies. However, until now, the mass spectrometric analysis of…
-
Artikel Jurnal Teks lengkap
The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma
The melanoma-associated antigens Melan-A and NY-ESO-1 stimulate different T-cell responses in late-stage melanoma patients. Either CD4(+) or CD8(+) T-cell reactivity against NY-ESO-1 was associated with better prognosis, but for Melan-A, only CD8(+) but not CD4(+) T-cell responses were associated…
-
Artikel Jurnal Teks lengkap
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy
Increasing numbers of trials employing anti-PD-1 immunotherapy emphasize the requirement for predictive biomarkers of clinical response. Many studies examine the cell surface expression of PD-1 and other key regulators of T-cell activation and inhibition. Here, we compared common commercially…
-
Artikel Jurnal Teks lengkap
Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
BACKGROUND: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Based on previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic melanoma patients were treated with this combination…
-
Artikel Jurnal Teks lengkap
Increased CCL17 serum levels are associated with improved survival in advanced melanoma
BACKGROUND: Prognostic factors of melanoma patients with distant metastases remain poorly established. This study aimed to compare the prognostic impact of putative serum biomarkers, namely S100B, YKL-40 or CCL17, in stage IV melanoma patients. PATIENTS AND METHODS: Serum concentrations were…
-
Artikel Jurnal Teks lengkap
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma
BACKGROUND: The incidence of melanoma, particularly in older patients, has steadily increased over the past few decades. Activating mutations of BRAF, the majority occurring in BRAFV600, are frequently detected in melanoma; however, the prognostic significance remains unclear. This study aimed to…
-
Artikel Jurnal Teks lengkap
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
BACKGROUND: Despite impressive response rates, most patients with advanced melanoma ultimately progress following therapy with B-Raf proto-oncogene (BRAF) inhibitors (BRAFi). Therefore, frequent radiologic assessments are necessary, and reliable serum biomarkers would be beneficial for disease…
-
Artikel Jurnal Teks lengkap
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
BACKGROUND: This study investigated survival probabilities and prognostic factors in sentinel lymph node biopsy (SLNB) staged patients with cutaneous melanoma (CM) with the aim of defining subgroups of patients who are at higher risk for recurrences and who should be considered for adjuvant…
-
Artikel Jurnal Teks lengkap
The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
Natural killer T (NKT) cells represent a cell subpopulation that combines characteristics of natural killer (NK) cells and T cells. Through their endogenous T-cell receptors (TCRs), they reveal a pronounced intrinsic anti-tumor activity. Thus, a NKT cell transfected with a chimeric antigen receptor…
-
Artikel Jurnal Teks lengkap
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One…
-
Artikel Jurnal Teks lengkap
BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
BACKGROUND: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. PATIENTS AND METHODS: We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started…
-
Artikel Jurnal Teks lengkap
Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
BACKGROUND: Prognostic factors of melanoma with distant metastasis and systemic treatment are only poorly established. This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment. PATIENTS AND…
-
Artikel Jurnal Teks lengkap
Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour
BACKGROUND: A direct comparison of prognosis between patients with regional lymph node metastases (LNM) detected synchronously with the primary melanoma (primary LNM), patients who developed their first LNM subsequently (secondary LNM) and those with initial LNM in melanoma with unknown primary…
-
Artikel Jurnal Teks lengkap
Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
BACKGROUND: Prognosis of patients with loco-regional skin metastases has not been analyzed in detail and the presence or absence of concurrent lymph node metastasis represents the only established prognostic factor thus far. Most studies were limited to patients already presenting with skin lesions…
-
Artikel Jurnal Teks lengkap
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
Systemic high-dose interleukin-2 (IL-2) treatment achieves long-term survival in a subset of advanced patients with melanoma. As we reported previously, intratumoral IL-2 induced complete local responses in more than 60% of melanoma patients. This study aimed to analyze the long-term outcome of 72…